Tenofovir Disoproxil Fumarate (TDF) Dosing and Alternatives in Patients with Renal Impairment
1. Dose Adjustment of TDF Based on Creatinine Clearance
- In patients with chronic kidney disease, TDF dosing must be adjusted according to creatinine clearance (CrCl):
- CrCl ≥ 50 mL/min → 300 mg every 24 h
- CrCl 30‑49 mL/min → 300 mg every 48 h
- CrCl 10‑29 mL/min → 300 mg every 72‑96 h
- CrCl < 10 mL/min (no renal replacement) → TDF not recommended
- Hemodialysis → 300 mg once weekly or after ~12 h of dialysis【1】【2】
Dose‑adjustment table
| Creatinine Clearance (mL/min) | Recommended TDF Dose |
|---|---|
| ≥ 50 | 300 mg every 24 h |
| 30‑49 | 300 mg every 48 h |
| 10‑29 | 300 mg every 72‑96 h |
| < 10 (no dialysis) | Not recommended |
| Hemodialysis | 300 mg weekly or post‑dialysis (~12 h) |
2. Preferred Antiviral Alternatives for Patients with Reduced Renal Function
- For individuals with estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m² or at risk for renal decline, first‑line therapy should favor Entecavir, Tenofovir Alafenamide (TAF), or Besifovir rather than TDF【4】【5】【1】.
2.1 Treatment‑naïve patients
| eGFR (mL/min/1.73 m²) | Preferred Regimen |
|---|---|
| ≥ 15 (no dialysis) | TAF 25 mg daily or Entecavir (dose‑adjusted)【4】【5】 |
| < 15 (no dialysis) | Entecavir only (TAF not indicated)【4】【5】 |
- Entecavir dose adjustment for CrCl < 50 mL/min: 0.25 mg daily or 0.5 mg every 48 h in treatment‑naïve patients【1】【2】.
2.2 Contraindications for Alternative Agents
- TAF is contraindicated when CrCl < 15 mL/min【6】【7】【1】.
- Besifovir is contraindicated when CrCl < 50 mL/min【6】【7】【1】.
3. Renal Benefits of Switching from TDF to Alternative Agents
- TDF → TAF: After 48 weeks, median eGFR increased by +0.94 mL/min, whereas continued TDF showed a decline of ‑2.74 mL/min【4】【5】.
- TDF → Besifovir: eGFR returned to baseline by week 144; TDF caused a decline of ‑7.8 mL/min at week 48【4】【5】【7】.
- TDF → TAF (extended follow‑up): At week 96, eGFR improved by +4.2 mL/min compared with a ‑0.9 mL/min change in the TDF‑continuation group at week 144【4】【5】.
4. Indicators of Renal Deterioration and Recommended Actions
Warning thresholds indicating the need for intervention:
- eGFR < 60 mL/min/1.73 m²【4】【5】【1】
- Proteinuria or urine albumin‑creatinine ratio > 30 mg/g【4】【5】【1】
- Serum phosphate < 2.5 mg/dL【4】【5】【1】
Management steps when renal decline is identified:
5. Baseline and Ongoing Renal Monitoring
- Before initiating TDF: obtain serum creatinine, calculate eGFR, and assess urine glucose and protein【1】.
- During therapy: perform renal function tests at clinically appropriate intervals (e.g., every 3–6 months)【1】.
- In patients with chronic kidney disease: also monitor serum phosphate levels【1】.
- High‑risk factors warrant closer surveillance (every 6–12 months): age > 50 years, uncontrolled hypertension, and diabetes mellitus【1】.
6. Populations Lacking Specific Dosing Guidance
- No evidence‑based dosing recommendations exist for pediatric patients with renal impairment【1】.
Renal Management of Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B
1. Dose adjustment of TDF according to renal function
- The Korean Association for the Study of the Liver (2022) recommends reducing the TDF dose based on creatinine clearance (CrCl) or estimated glomerular filtration rate (eGFR) (≥50 mL/min → 300 mg every 24 h; 30‑49 → 300 mg every 48 h; 10‑29 → 300 mg every 72‑96 h; <10 mL/min with dialysis → 300 mg weekly; <10 mL/min without dialysis → not indicated)【8】.
| CrCl / eGFR (mL/min) | Recommended TDF regimen |
|---|---|
| ≥50 | 300 mg every 24 h |
| 30‑49 | 300 mg every 48 h |
| 10‑29 | 300 mg every 72‑96 h |
| <10 with dialysis | 300 mg every 7 days (or after ~12 h dialysis) |
| <10 without dialysis | Contra‑indicated |
2. Preferred antiviral agents for patients with renal impairment
- Treatment‑naïve chronic HBV patients with eGFR < 60 mL/min/1.73 m² should be started on Tenofovir Alafenamide (TAF), Entecavir, or Besifovir rather than TDF【9】【10】【11】.
- Patients already receiving TDF who develop renal dysfunction should be switched to TAF, Entecavir, or Besifovir【9】【11】.
3. Renal benefits of switching from TDF to alternative agents
| Switch | Outcome (eGFR change) | Follow‑up | Evidence |
|---|---|---|---|
| TDF → TAF (48 weeks) | +0.94 mL/min vs. ‑2.74 mL/min with continued TDF | 48 weeks | 【12】【13】 |
| TDF → TAF (96 weeks) | +4.2 mL/min vs. ‑0.9 mL/min with continued TDF | 96 weeks | 【8】【12】 |
| TDF → Besifovir (144 weeks) | eGFR returns to baseline (no net loss) vs. ‑7.8 mL/min decline with TDF at week 48 | 144 weeks | 【8】【12】【14】 |
These data indicate that switching to a less nephrotoxic agent yields clinically meaningful improvements in renal function.
4. Clinical triggers for dose reduction, drug switch, or discontinuation
- Immediate evaluation for stopping or switching TDF is warranted when any of the following are present:
5. Specific dosing recommendations for alternative agents
5.1 Tenofovir Alafenamide (TAF)
- eGFR ≥ 15 mL/min → 25 mg once daily【8】【13】【14】.
- eGFR < 15 mL/min with dialysis → 25 mg once daily【8】【13】.
- eGFR < 15 mL/min without dialysis → Contra‑indicated【8】【13】【14】.
5.2 Entecavir (for treatment‑naïve patients)
| CrCl (mL/min) | Recommended dose |
|---|---|
| ≥ 50 | 0.5 mg once daily |
| 30‑49 | 0.25 mg once daily or 0.5 mg every 48 h |
| 10‑29 | 0.15 mg once daily or 0.5 mg every 72 h【8】【12】【14】 |
5.3 Besifovir
| CrCl (mL/min) | Recommended dose |
|---|---|
| ≥ 50 | 150 mg once daily |
| 30‑49 | 150 mg every 48 h |
| 15‑29 | 150 mg every 96 h |
| < 15 | Contra‑indicated【8】【12】【14】 |
6. Evidence supporting drug switching over simple dose reduction
- Studies cited by the Korean Association for the Study of the Liver (2022) demonstrate that merely adjusting the TDF dose without switching does not provide the same renal benefit as changing to TAF, Entecavir, or Besifovir【12】【13】【11】.
All facts are drawn from peer‑reviewed sources with citation identifiers as indicated.
Renal Dose Adjustment and Management of Tenofovir Disoproxil Fumarate (TDF)
FDA‑Approved Dosing Adjustments for TDF by Creatinine Clearance
| Creatinine Clearance (mL/min) | Recommended TDF Dosing Interval |
|---|---|
| ≥ 50 | 300 mg every 24 h |
| 30–49 | 300 mg every 48 h |
| 10–29 | 300 mg every 72–96 h |
| < 10 (no dialysis) | Not recommended |
| Hemodialysis | 300 mg once weekly or after dialysis (≈12 h) |
Based on the FDA‑approved schedule as reported in Clinical and Molecular Hepatology [15][16]
When Initiation of TDF Should Be Avoided
TDF should not be started in patients whose baseline estimated glomerular filtration rate (eGFR) is < 60 mL/min/1.73 m²; preferred agents are tenofovir alafenamide (TAF), entecavir, or besifovir.
Evidence from large phase‑3 trials shows a median eGFR decline of *‑5.0 mL/min with TDF versus ‑0.3 mL/min* with TAF over 96 weeks in patients with renal‑risk factors [16][17]15.Additional contraindications to initiating TDF include:
Preferred Antiviral Alternatives in Renal Impairment
Tenofovir Alafenamide (TAF)
- Dose: 25 mg once daily for patients with CrCl ≥ 15 mL/min. 16
- Contraindication: CrCl < 15 mL/min without dialysis. [15][16]
- Renal advantage: Minimal impact on renal function compared with TDF. [15][16]
Entecavir (for treatment‑naïve patients)
| Creatinine Clearance (mL/min) | Recommended Entecavir Dose |
|---|---|
| ≥ 50 | 0.5 mg once daily |
| 30–49 | 0.25 mg once daily or 0.5 mg every 48 h |
| 10–29 | 0.15 mg once daily or 0.5 mg every 72 h |
| < 10 or on hemodialysis | 0.05 mg once daily or 0.5 mg every 7 days |
Dosing recommendations derived from Clinical and Molecular Hepatology [15][16]
Besifovir
Switching Strategy When Renal Function Deteriorates on TDF
If eGFR declines *> 25 % from baseline and falls < 50 mL/min/1.73 m²*, switch from TDF to TAF, entecavir, or besifovir rather than merely adjusting the TDF interval. [16][17]
Renal recovery data (cited):
Monitoring Red Flags Requiring Immediate Intervention
- New or worsening proteinuria/albuminuria (urine albumin‑to‑creatinine ratio > 30 mg/g) [16][17]
- Euglycemic glycosuria indicating proximal tubular dysfunction 18
- Serum phosphate < 2.5 mg/dL [16][17]
HIV/HBV Coinfection Consideration
When treating HIV/HBV coinfection, TDF *must be combined* with other antiretroviral agents; TDF monotherapy can select for HIV resistance. 15
Antiviral Management of Chronic Hepatitis B in Patients Receiving Dialysis
First‑Line Antiviral Selection
- Entecavir is the preferred first‑line agent for chronic hepatitis B in dialysis patients, administered at 0.05 mg daily or 0.5 mg weekly after each dialysis session 19.
- Entecavir demonstrates superior safety in this population, showing minimal nephrotoxic potential and no adverse impact on bone mineral density 20.
- For treatment‑naïve individuals with very low creatinine clearance (≤10 mL/min) or on dialysis, the recommended entecavir dose is 0.05 mg daily or 0.5 mg weekly 21.
- In patients with lamivudine‑resistant hepatitis B on dialysis, the entecavir dose should be increased to 0.1 mg daily or 1 mg weekly 22.
- Entecavir must be given after dialysis to avoid immediate removal of the drug from the circulation 19.
Tenofovir Disoproxil Fumarate (TDF) for Resistant Cases
- TDF is the drug of choice for nucleoside‑resistant (e.g., lamivudine‑resistant) hepatitis B in dialysis patients, dosed at 300 mg once weekly or approximately 12 hours after the dialysis session 20.
- TDF is contraindicated in patients with creatinine clearance < 10 mL/min who are not receiving dialysis 20.
- Post‑dialysis administration is essential for TDF to achieve therapeutic plasma concentrations 23.
Tenofovir Alafenamide (TAF) Considerations
- TAF offers improved renal safety compared with TDF, but data in dialysis populations are limited; a provisional dose of 25 mg daily may be considered for patients with creatinine clearance < 15 mL/min who are on dialysis 20.
- TAF is contraindicated in patients with creatinine clearance < 15 mL/min who are not on dialysis 20.
Alternative Antivirals and Dosing
- Lamivudine can be used in dialysis with an initial dose of 35 mg followed by 10 mg daily for very low creatinine clearance (<5 mL/min) 22.
- Telbivudine dosing for end‑stage renal disease is 600 mg every 96 hours; serum creatine‑kinase levels should be monitored because of myositis risk 22.
- Adefovir is associated with significant nephrotoxicity; when used, a dose of 10 mg weekly after dialysis is recommended, but it is not advised for creatinine clearance < 10 mL/min 24.
- Besifovir shows a more favorable renal safety profile than TDF, yet it is not indicated for patients with creatinine clearance < 15 mL/min due to insufficient clinical data 20.
Virologic and Safety Monitoring
- Serum HBV DNA should be measured every 1–3 months during the initial treatment phase and every 3–6 months thereafter; the therapeutic goal is undetectable HBV DNA (<10–15 IU/mL) 22.
- Renal function tests are recommended every 3–6 months even in patients already on dialysis to assess residual kidney function 24.
- For TDF therapy, monitor serum phosphate and evaluate for proteinuria; for telbivudine, monitor serum creatine‑kinase 20, 22.
Clinical Pitfalls and Dose Adjustment
- All nucleos(t)ide analogues require dose modification in dialysis; using standard doses without adjustment can lead to drug accumulation and toxicity 23.
- Creatinine clearance should be calculated using ideal (lean) body weight rather than actual body weight 20.
- Administration must always occur after dialysis; pre‑dialysis dosing results in rapid drug removal and sub‑therapeutic exposure 19.
- Therapy should be continued indefinitely, even after achieving undetectable HBV DNA, to prevent hepatitis flares 22.
Management of Primary Non‑Response and Resistance
- If HBV DNA declines by less than 2 log₁₀ IU/mL after ≥6 months of therapy, an immediate switch to or addition of a more potent antiviral is advised 23.
Special Populations
- Patients on peritoneal dialysis follow the same entecavir dosing regimens as those on hemodialysis (0.05 mg daily or 0.5 mg weekly for treatment‑naïve individuals) 21.